Last reviewed · How we verify
CsA+MMF+CS
This combination suppresses the immune system through multiple pathways: cyclosporine inhibits T-cell activation, mycophenolate mofetil blocks lymphocyte proliferation, and corticosteroids broadly dampen inflammatory responses.
This combination suppresses the immune system through multiple pathways: cyclosporine inhibits T-cell activation, mycophenolate mofetil blocks lymphocyte proliferation, and corticosteroids broadly dampen inflammatory responses. Used for Prevention of organ rejection in renal transplant recipients, Prevention of organ rejection in cardiac transplant recipients, Prevention of organ rejection in hepatic transplant recipients.
At a glance
| Generic name | CsA+MMF+CS |
|---|---|
| Sponsor | Pfizer |
| Drug class | Immunosuppressive combination therapy |
| Target | Calcineurin (CsA); IMPDH type II (MMF); glucocorticoid receptor (CS) |
| Modality | Small molecule |
| Therapeutic area | Immunology / Transplantation |
| Phase | FDA-approved |
Mechanism of action
Cyclosporine (CsA) binds calcineurin to prevent T-cell receptor signaling and IL-2 production. Mycophenolate mofetil (MMF) selectively inhibits inosine monophosphate dehydrogenase, depleting guanosine nucleotides needed for lymphocyte proliferation. Corticosteroids (CS) reduce inflammatory cytokine production and immune cell trafficking. Together, these agents provide synergistic immunosuppression for transplant rejection prevention.
Approved indications
- Prevention of organ rejection in renal transplant recipients
- Prevention of organ rejection in cardiac transplant recipients
- Prevention of organ rejection in hepatic transplant recipients
Common side effects
- Nephrotoxicity
- Hypertension
- Hyperglycemia
- Infection
- Gastrointestinal disturbance
- Tremor
- Gingival hyperplasia
Key clinical trials
- SCHEDULE Follow Up Visit 5-7 yr (PHASE4)
- Open Label Comparative Study Of De Novo Renal Allograft Recipients Receiving CSA + MMF + Corticosteroids Versus CSA + Rapamune + Corticosteroids (PHASE4)
- SCHEDULE - Scandinavian Heart Transplant Everolimus de Novo Study With Early Calcineurin Inhibitor (CNI) Avoidance (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CsA+MMF+CS CI brief — competitive landscape report
- CsA+MMF+CS updates RSS · CI watch RSS
- Pfizer portfolio CI